Form 4: Acrivon Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics, Inc., sold 1,142 shares of common stock on August 4, 2026 for $1.57 per share.
Summary
- Open-market sale: disposed of 1,142 Common Stock at $1.57 ($1,793) on August 4, 2026; holds 66,008 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,793 of stock on the open market.
Insider Transactions
Adam D. Levy — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-04 | Open-market sale | Common Stock | 1,142 | $2 | $1.8K | 66,008 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-04 | Open-market sale (1,142 shares) |
Keywords
insider transaction, Form 4, ACRV, Acrivon Therapeutics, Inc., bearish, Adam D. Levy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.